Avinger Inc (AVGR)

$1.50 0.01 (0.67%)

19:56 EDT AVGR Stock Quote Delayed 30 Minutes

Louis Navellier and the InvestorPlace Research Staff

Target Top-Line Growth and Compelling Patient Outcomes with Avinger

By Louis Navellier and the InvestorPlace Research Staff, Editor, Growth Investor Mar 30, 2021

It's been reported that AVGR stock is popular among Robinhood traders. That's fine, but it's more important to see the company's potential.

AVGR Stock: The Social Media Buzz That Has Avinger Shares Soaring

AVGR Stock: 11 Things to Know About Avinger as Shares Rocket Higher

AVGR Stock: 6 Things to Know About ‘Robinhood’s Hot Penny Stock to Buy’ Avinger

More Articles

Volume:

Previous Close -

Market Cap 13.60M

PE Ratio -0.03

EPS -56.99

Volume (Avg. Vol.) 1.85M

Day's Range 1.44 - 1.51

52-Week Range 0.21 - 2.67

Dividend & Yield N/A (N/A)

AVGR Stock Predictions, Articles, and Avinger Inc News

From InvestorPlace
From the Web

Avinger News: AVGR Stock Down 8% Following FDA Approval

By William White, InvestorPlace Writer Sep 11, 2020

Avinger (AVGR) news for Friday concerning approval from the FDA for one of its medical devices has AVGR stock on the move.

Avinger Inc Stock Goes Gangbusters on FDA Approval of Next-Gen Medical Device

By William White, InvestorPlace Writer May 23, 2018

Avinger (AVGR) is performing outstandingly well today on news of U.S. Food and Drug Administration approval for a new medical device.

Tempur Sealy International Inc (TPX) Leads 30 Notable Investor Filings

By Fintel May 11, 2017

13GF and 13D Filings are windows into the world of activist investors activity. We look at Tempur Sealy International Inc (TPX) and 20 other notable filings

Avinger Provides Update on Tigereye(TM) Commercial Launch

From Avinger, Inc. Apr 8, 2021

REDWOOD CITY, CA / ACCESSWIRE / April 8, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today provided an update on the commercial launch of Tigereye CTO Crossing catheters for the treatment of PAD. Following limited launch in the fourth quarter of 2020, Avinger

Avinger: Q4 Earnings Insights

From Benzinga Mar 11, 2021

Avinger (NASDAQ:AVGR) reported Q4 results on Thursday afternoon. Quarterly Results Earnings per share were up 87.93% over the past year to ($0.07), which missed the estimate of ($...

Avinger Reports Fourth Quarter 2020 Financial Results

From Avinger, Inc. Mar 11, 2021

19% Sequential Increase in Total Revenue Tigereye™ Drives 38% Sequential Growth in Image-Guided CTO Revenue REDWOOD CITY, CA / ACCESSWIRE / March 11, 2021 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today reported results for the fourth quarter ended December

Earnings Outlook For Avinger

From Benzinga Mar 10, 2021

Avinger (NASDAQ:AVGR) announces its next round of earnings this Thursday, March 11. Here is Benzinga's everything-that-matters guide for this Thursday's Q4 earnings...

Avinger Technical Levels To Watch Following Patent News

From Benzinga Mar 2, 2021

Avinger Inc. (NASDAQ:AVGR) is forming what technical traders call a pennant on the...

Earnings Scheduled For March 11, 2021

From Benzinga Mar 11, 2021

Companies Reporting Before The Bell • Celsius Holdings (NASDAQ:CELH) is estimated to report quarterly earnings at $0.02 per share on revenue of $34.63 million. •...